Literature DB >> 17109786

Long-term use of the ketogenic diet in the treatment of epilepsy.

Darcy K Groesbeck1, Renee M Bluml, Eric H Kossoff.   

Abstract

Long-term outcomes of the ketogenic diet in the treatment of epilepsy have not previously been reported. A retrospective chart review of children treated with the ketogenic diet for more than 6 years at the Johns Hopkins Hospital was performed. The response was documented at clinic visits and by telephone contacts; laboratory studies were obtained approximately every 6 to 12 months. Satisfaction and tolerability were assessed by means of a brief parental telephone questionnaire. In all, 28 patients (15 males, 13 females), currently aged 7 to 23 years, were identified. The median baseline seizure frequency per week at diet onset was 630 (range 1-1400). Diet duration ranged from 6 to 12 years; 19 remain on the diet currently. After 6 years or more, 24 children experienced a more than 90% decrease in seizures, and 22 parents reported satisfaction with the diet's efficacy. Ten children were at less than the 10th centile for height at diet initiation; this number increased to 23 at the most recent follow-up (p=0.001). Kidney stones occurred in seven children and skeletal fractures in six. After 6 years or more the mean cholesterol level was 201mg/dl, high-density lipoprotein was 54mg/dl, low-density lipoprotein was 129mg/dl, and triglycerides were 97mg/dl. Efficacy and overall tolerability for children are maintained after prolonged use of the ketogenic diet. However, side effects, such as slowed growth, kidney stones, and fractures, should be monitored closely.

Entities:  

Mesh:

Year:  2006        PMID: 17109786     DOI: 10.1017/S0012162206002143

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  34 in total

Review 1.  State of the ketogenic diet(s) in epilepsy.

Authors:  Jennifer Huffman; Eric H Kossoff
Journal:  Curr Neurol Neurosci Rep       Date:  2006-07       Impact factor: 5.081

2.  Danger in the pipeline for the ketogenic diet?

Authors:  Eric Kossoff
Journal:  Epilepsy Curr       Date:  2014 Nov-Dec       Impact factor: 7.500

Review 3.  Ketogenic diets, mitochondria, and neurological diseases.

Authors:  Lindsey B Gano; Manisha Patel; Jong M Rho
Journal:  J Lipid Res       Date:  2014-05-20       Impact factor: 5.922

Review 4.  The changing face of dietary therapy for epilepsy.

Authors:  Ludovica Pasca; Valentina De Giorgis; Joyce Ann Macasaet; Claudia Trentani; Anna Tagliabue; Pierangelo Veggiotti
Journal:  Eur J Pediatr       Date:  2016-09-01       Impact factor: 3.183

Review 5.  Dietary therapies for epilepsy: future research.

Authors:  Sudha K Kessler; Elizabeth G Neal; Carol S Camfield; Eric H Kossoff
Journal:  Epilepsy Behav       Date:  2011-03-26       Impact factor: 2.937

Review 6.  Targeting the Warburg effect for cancer treatment: Ketogenic diets for management of glioma.

Authors:  Angela Poff; Andrew P Koutnik; Kathleen M Egan; Solmaz Sahebjam; Dominic D'Agostino; Nagi B Kumar
Journal:  Semin Cancer Biol       Date:  2017-12-30       Impact factor: 15.707

Review 7.  Osteoporosis Associated with Epilepsy and the Use of Anti-Epileptics-a Review.

Authors:  Sandra J Petty; Helen Wilding; John D Wark
Journal:  Curr Osteoporos Rep       Date:  2016-04       Impact factor: 5.096

Review 8.  Management of the patient with medically refractory epilepsy.

Authors:  Tiziana Granata; Nicola Marchi; Erin Carlton; Chaitali Ghosh; Jorge Gonzalez-Martinez; Andreas V Alexopoulos; Damir Janigro
Journal:  Expert Rev Neurother       Date:  2009-12       Impact factor: 4.618

9.  Neuropsychiatric morbidity in adolescent and adult succinic semialdehyde dehydrogenase deficiency patients.

Authors:  Ina Knerr; K Michael Gibson; Cornelis Jakobs; Phillip L Pearl
Journal:  CNS Spectr       Date:  2008-07       Impact factor: 3.790

10.  Long-term impact of the ketogenic diet on growth and resting energy expenditure in children with intractable epilepsy.

Authors:  Veronique Groleau; Joan I Schall; Virginia A Stallings; Christina A Bergqvist
Journal:  Dev Med Child Neurol       Date:  2014-04-20       Impact factor: 5.449

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.